United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $259.60, for a total value of $2,076,800.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $33,748. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Trading Up 0.6 %
Shares of NASDAQ UTHR opened at $261.70 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.39 and a current ratio of 9.68. The business's 50 day moving average price is $270.84 and its 200-day moving average price is $241.24. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $283.09. The company has a market cap of $11.93 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.55 and a beta of 0.62.
Get
United Therapeutics alerts:
United Therapeutics (NASDAQ:UTHR – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping the consensus estimate of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The firm had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. On average, sell-side analysts expect that United Therapeutics Co. will post 16.57 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Charter Oak Capital Management LLC bought a new position in United Therapeutics in the second quarter worth approximately $25,000. Cullen Frost Bankers Inc. bought a new position in United Therapeutics in the second quarter worth approximately $26,000. Guardian Wealth Advisors LLC bought a new position in United Therapeutics in the third quarter worth approximately $27,000. Ronald Blue Trust Inc. bought a new position in United Therapeutics in the second quarter worth approximately $28,000. Finally, Hallmark Capital Management Inc. bought a new position in United Therapeutics in the second quarter worth approximately $33,000. Institutional investors own 95.63% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently commented on UTHR. UBS Group began coverage on United Therapeutics in a research report on Tuesday, December 6th. They issued a "buy" rating and a $320.00 target price on the stock. The Goldman Sachs Group began coverage on United Therapeutics in a research report on Monday, December 5th. They issued a "sell" rating and a $230.00 target price on the stock. Argus boosted their target price on United Therapeutics from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Wednesday, January 11th. Wedbush boosted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an "outperform" rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $283.64.
About United Therapeutics
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
